Gina Ahn

Gina Ahn inquired about the differentiation of the ArrowMapT program from J&J's failed anti-tau antibody and the continued confidence in the target. She also asked about the visibility for launching a CBOT study and potential Sarepta milestone triggers expected in 2026.

Answer

James Hamilton, Chief Medical Officer and Head of R&D, highlighted ArrowMapT's differentiation through siRNA delivery across the blood-brain barrier into neurons to silence tau expression, targeting both intracellular and extracellular tau, unlike IV monoclonals. He stated that the company is moving quickly on the CBOT study for ArrowDiamond PA, expecting to know if they have a viable drug by summer, and plans to roll directly into pivotal studies if data are positive. Dan Apel, CFO, confirmed that the first of five $50 million Sarepta annuities is expected in February 2026.

Gina Ahn from Bank of America asked about the differentiation of Arrowhead's ARO-MAPT program from J&J's failed anti-tau antibody, the company's continued confidence in the tau target, visibility on launching a CBOT study for ArrowDiamond PA, and expected Sarepta milestone triggers in 2026.

Answer

James Hamilton, Chief Medical Officer and Head of R&D for Arrowhead Pharmaceuticals, highlighted ARO-MAPT's differentiation through its proprietary delivery system, enabling blood-brain barrier penetration and silencing of intracellular tau expression, contrasting with monoclonal antibodies targeting extracellular tau. He stated that the company aims to roll directly into pivotal studies for ArrowDiamond PA after phase I/II, with summer 2026 data informing the timeline, and confirmed a $50 million Sarepta annuity milestone expected in February 2026, as corroborated by Dan Apel, Chief Financial Officer.